GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Vaccine Inc (SZSE:301207) » Definitions » EV-to-Revenue

Hualan Biological Vaccine (SZSE:301207) EV-to-Revenue : 7.55 (As of Jul. 14, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Hualan Biological Vaccine EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hualan Biological Vaccine's enterprise value is ¥8,438 Mil. Hualan Biological Vaccine's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ¥1,118 Mil. Therefore, Hualan Biological Vaccine's EV-to-Revenue for today is 7.55.

The historical rank and industry rank for Hualan Biological Vaccine's EV-to-Revenue or its related term are showing as below:

SZSE:301207' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.12   Med: 7.22   Max: 28.34
Current: 7.55

During the past 8 years, the highest EV-to-Revenue of Hualan Biological Vaccine was 28.34. The lowest was 3.12. And the median was 7.22.

SZSE:301207's EV-to-Revenue is ranked better than
52.01% of 994 companies
in the Biotechnology industry
Industry Median: 8.23 vs SZSE:301207: 7.55

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-14), Hualan Biological Vaccine's stock price is ¥17.33. Hualan Biological Vaccine's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ¥1.87. Therefore, Hualan Biological Vaccine's PS Ratio for today is 9.25.


Hualan Biological Vaccine EV-to-Revenue Historical Data

The historical data trend for Hualan Biological Vaccine's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Vaccine EV-to-Revenue Chart

Hualan Biological Vaccine Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial - - 8.83 6.12 7.75

Hualan Biological Vaccine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 3.65 6.61 7.75 7.39

Competitive Comparison of Hualan Biological Vaccine's EV-to-Revenue

For the Biotechnology subindustry, Hualan Biological Vaccine's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Vaccine's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Vaccine's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hualan Biological Vaccine's EV-to-Revenue falls into.


;
;

Hualan Biological Vaccine EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hualan Biological Vaccine's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8438.220/1117.872
=7.55

Hualan Biological Vaccine's current Enterprise Value is ¥8,438 Mil.
Hualan Biological Vaccine's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,118 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Vaccine  (SZSE:301207) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hualan Biological Vaccine's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=17.33/1.874
=9.25

Hualan Biological Vaccine's share price for today is ¥17.33.
Hualan Biological Vaccine's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.87.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Vaccine EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hualan Biological Vaccine's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Vaccine Business Description

Traded in Other Exchanges
N/A
Address
No. 1, No. 1, Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.
Executives
Lou Yuan Cheng Supervisors

Hualan Biological Vaccine Headlines

No Headlines